Dow Jones Newswires: Roche’s Tecentriq shows further good survival rates as cancer treatment

The study earlier this year met its primary endpoint, showing good recurrence-free survival rates in patients treated with Tecentriq and Avastin for early-stage epatocellular carcinoma.

Previous post Gen Zs don’t have a lot of money, but they’re traveling anyway
Next post : Netflix apologizes as ‘Love Is Blind’ reunion show is delayed by glitch